Chimeric IgG Fc receptor compositions with CD64 extracellular domains

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12590138B2 to Regents of the University of Minnesota for chimeric IgG Fc receptor compositions comprising CD64 extracellular domains. The patent covers recombinant immune cells engineered to express heterologous IgG Fc receptors with ITAM-mediated cell signaling capabilities for therapeutic applications. This patent grant provides the university with enforceable exclusive rights to the disclosed biotechnology.

View original document View source feed page

What changed

USPTO issued patent US12590138B2 on March 31, 2026, to Regents of the University of Minnesota, covering recombinant immune cells expressing heterologous IgG Fc receptors with CD64 extracellular domains capable of binding IgG Fc regions. The chimeric receptors include transmembrane and intracellular domains with ITAM signaling functionality. Inventors include Jianming Wu, Bruce Kenneth Walcheck, Robert Harrison Hullsiek, Yungfang Li, and Hemant Kumar Mishra. The patent contains 9 claims and has CPC classifications spanning therapeutic proteins (A61K), antibodies (C07K), and cell compositions (C12N).

This patent grant does not impose immediate compliance obligations on regulated entities. Companies developing Fc receptor-based cell therapies should review this patent to assess potential freedom-to-operate implications for their programs. The patent is enforceable upon issuance and provides the assignee exclusive rights to practice the claimed inventions. No immediate regulatory action is required; entities should consult patent counsel for licensing inquiries or validity assessments.

Source document (simplified)

← USPTO Patent Grants

Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64

Grant US12590138B2 Kind: B2 Mar 31, 2026

Assignee

Regents of the University of Minnesota

Inventors

Jianming Wu, Bruce Kenneth Walcheck, Robert Harrison Hullsiek, Yungfang Li, Hemant Kumar Mishra

Abstract

A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

CPC Classifications

A61K 38/177 A61K 38/1774 A61K 40/11 A61K 40/15 A61K 40/31 A61K 40/33 A61K 40/42 A61K 40/4224 A61K 2239/15 A61K 2239/21 A61K 2239/22 C07K 14/70503 C07K 14/70535 C07K 19/00 C07K 2319/00 C07K 2319/50 C07K 2319/02 C07K 2319/03 C07K 2319/74 C07K 16/30 C12N 5/0637 C12N 5/0646